Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of phosphatidylinositol 4-kinase type II beta as HLA class II-restricted target in graft versus leukemia reactivity.
Griffioen M, van der Meijden ED, Slager EH, Honders MW, Rutten CE, van Luxemburg-Heijs SA, von dem Borne PA, van Rood JJ, Willemze R, Falkenburg JH. Griffioen M, et al. Among authors: rutten ce. Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3837-42. doi: 10.1073/pnas.0712250105. Epub 2008 Mar 3. Proc Natl Acad Sci U S A. 2008. PMID: 18316730 Free PMC article.
Alloreactive effector T cells require the local formation of a proinflammatory environment to allow crosstalk and high avidity interaction with nonhematopoietic tissues to induce GVHD reactivity.
van der Zouwen B, Kruisselbrink AB, Jordanova ES, Rutten CE, von dem Borne PA, Falkenburg JH, Jedema I. van der Zouwen B, et al. Among authors: rutten ce. Biol Blood Marrow Transplant. 2012 Sep;18(9):1353-67. doi: 10.1016/j.bbmt.2012.06.017. Epub 2012 Jul 11. Biol Blood Marrow Transplant. 2012. PMID: 22796533 Free article.
Patient HLA-DP-specific CD4+ T cells from HLA-DPB1-mismatched donor lymphocyte infusion can induce graft-versus-leukemia reactivity in the presence or absence of graft-versus-host disease.
Rutten CE, van Luxemburg-Heijs SA, Halkes CJ, van Bergen CA, Marijt EW, Oudshoorn M, Griffioen M, Falkenburg JH. Rutten CE, et al. Biol Blood Marrow Transplant. 2013 Jan;19(1):40-8. doi: 10.1016/j.bbmt.2012.07.020. Epub 2012 Aug 4. Biol Blood Marrow Transplant. 2013. PMID: 22871556 Free article. Clinical Trial.
Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response.
van Bergen CA, van Luxemburg-Heijs SA, de Wreede LC, Eefting M, von dem Borne PA, van Balen P, Heemskerk MH, Mulder A, Claas FH, Navarrete MA, Honders WM, Rutten CE, Veelken H, Jedema I, Halkes CJ, Griffioen M, Falkenburg JH. van Bergen CA, et al. Among authors: rutten ce. J Clin Invest. 2017 Feb 1;127(2):517-529. doi: 10.1172/JCI86175. Epub 2017 Jan 9. J Clin Invest. 2017. PMID: 28067665 Free PMC article.
Discovery and Differential Processing of HLA Class II-Restricted Minor Histocompatibility Antigen LB-PIP4K2A-1S and Its Allelic Variant by Asparagine Endopeptidase.
Kremer AN, Bausenwein J, Lurvink E, Kremer AE, Rutten CE, van Bergen CAM, Kretschmann S, van der Meijden E, Honders MW, Mazzeo D, Watts C, Mackensen A, Falkenburg JHF, Griffioen M. Kremer AN, et al. Among authors: rutten ce. Front Immunol. 2020 Mar 11;11:381. doi: 10.3389/fimmu.2020.00381. eCollection 2020. Front Immunol. 2020. PMID: 32218783 Free PMC article.
25 results